CombiMatrix Corporation has announced that Universal Diagnostic Laboratories will market and distribute CombiMatrix's chromosomal microarray miscarriage analysis test for the evaluation of multiple pregnancy loss in both Northern and Southern California. Terms of the agreement were not disclosed.
“This is another example of leveraging channel partners to augment our direct sales team's efforts in expanding the distribution of our tests,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “Our miscarriage analysis test is now more accessible to women in our home state of California. We are pleased to partner with Universal Diagnostics Laboratories, which shares our commitment to high-touch, personalized service and excellent turnaround times.”
“This agreement demonstrates execution on a key aspect of our business strategy by expanding our portfolio of molecular diagnostics focused on women's health,” said Michael Mosunic, President and Chief Operating Officer of Universal Diagnostic Laboratories.
“Importantly, this test provides valuable information to women and their families about the reasons behind multiple miscarriages. We are particularly excited about the CombiMatrix test as chromosomal microarray analysis has shown to have superior diagnostic attributes over karyotyping for recurrent pregnancy loss.”